NL9301086A - Methoden voor toediening van taxol. - Google Patents

Methoden voor toediening van taxol. Download PDF

Info

Publication number: NL9301086A
Authority: NL; Netherlands
Prior art keywords: taxol; infusion; patients; patient; hours
Prior art date: 1992-08-03

Application number

NL9301086A

Other languages

English (en)

Dutch (nl)

Original Assignee

Squibb Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-03

Filing date

1993-06-22

Publication date

1994-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25448992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL9301086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-06-22 Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co

1994-03-01 Publication of NL9301086A publication Critical patent/NL9301086A/nl

Links

RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 160
229930012538 Paclitaxel Natural products 0.000 title claims abstract description 159
229960001592 paclitaxel Drugs 0.000 title claims abstract description 159
238000000034 method Methods 0.000 title claims description 34
206010028980 Neoplasm Diseases 0.000 claims abstract description 27
238000006243 chemical reaction Methods 0.000 claims abstract description 22
239000003814 drug Substances 0.000 claims abstract description 10
229940079593 drug Drugs 0.000 claims abstract description 9
238000002483 medication Methods 0.000 claims abstract 4
238000001802 infusion Methods 0.000 claims description 141
206010020751 Hypersensitivity Diseases 0.000 claims description 51
238000009101 premedication Methods 0.000 claims description 24
201000011510 cancer Diseases 0.000 claims description 21
206010033128 Ovarian cancer Diseases 0.000 claims description 15
230000000118 anti-neoplastic effect Effects 0.000 claims description 11
206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
239000000739 antihistaminic agent Substances 0.000 claims description 8
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
229960000520 diphenhydramine Drugs 0.000 claims description 7
150000003431 steroids Chemical class 0.000 claims description 7
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 5
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 5
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 5
229960000620 ranitidine Drugs 0.000 claims description 5
229940125715 antihistaminic agent Drugs 0.000 claims description 4
229940034982 antineoplastic agent Drugs 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
-1 decamethasone Chemical compound 0.000 claims description 4
229960000890 hydrocortisone Drugs 0.000 claims description 4
229960003291 chlorphenamine Drugs 0.000 claims description 3
229960001380 cimetidine Drugs 0.000 claims description 3
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 3
230000002045 lasting effect Effects 0.000 claims description 3
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
229960004618 prednisone Drugs 0.000 claims description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
229940044551 receptor antagonist Drugs 0.000 claims 2
239000002464 receptor antagonist Substances 0.000 claims 2
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims 1
SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 claims 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
229960002881 clemastine Drugs 0.000 claims 1
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 1
229940099401 dimethindene maleate Drugs 0.000 claims 1
229960001596 famotidine Drugs 0.000 claims 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
229960003910 promethazine Drugs 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 50
238000011275 oncology therapy Methods 0.000 abstract 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 26
208000033808 peripheral neuropathy Diseases 0.000 description 14
208000004235 neutropenia Diseases 0.000 description 13
229910052697 platinum Inorganic materials 0.000 description 13
208000024891 symptom Diseases 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
231100000419 toxicity Toxicity 0.000 description 11
230000001988 toxicity Effects 0.000 description 11
230000000694 effects Effects 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
230000007823 neuropathy Effects 0.000 description 7
201000001119 neuropathy Diseases 0.000 description 7
206010065553 Bone marrow failure Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
230000001387 anti-histamine Effects 0.000 description 6
210000003714 granulocyte Anatomy 0.000 description 6
206010037844 rash Diseases 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
229930182837 (R)-adrenaline Natural products 0.000 description 5
208000010201 Exanthema Diseases 0.000 description 5
229960003957 dexamethasone Drugs 0.000 description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229960005139 epinephrine Drugs 0.000 description 5
201000005884 exanthem Diseases 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
201000002364 leukopenia Diseases 0.000 description 5
239000008389 polyethoxylated castor oil Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
208000000059 Dyspnea Diseases 0.000 description 4
206010013975 Dyspnoeas Diseases 0.000 description 4
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
208000003455 anaphylaxis Diseases 0.000 description 4
208000006218 bradycardia Diseases 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
231100000228 neurotoxicity Toxicity 0.000 description 4
230000007135 neurotoxicity Effects 0.000 description 4
238000011268 retreatment Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
206010029350 Neurotoxicity Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010044221 Toxic encephalopathy Diseases 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
208000030961 allergic reaction Diseases 0.000 description 3
238000004820 blood count Methods 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
230000036471 bradycardia Effects 0.000 description 3
229940047120 colony stimulating factors Drugs 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
229960000935 dehydrated alcohol Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
231100000226 haematotoxicity Toxicity 0.000 description 3
230000036543 hypotension Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
206010003671 Atrioventricular Block Diseases 0.000 description 2
206010055113 Breast cancer metastatic Diseases 0.000 description 2
208000002633 Febrile Neutropenia Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010028116 Mucosal inflammation Diseases 0.000 description 2
201000010927 Mucositis Diseases 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000009104 chemotherapy regimen Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
231100000371 dose-limiting toxicity Toxicity 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
231100001022 leukopenia Toxicity 0.000 description 2
230000003908 liver function Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000008520 organization Effects 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
206010063119 Anaphylactoid shock Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
206010049765 Bradyarrhythmia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
206010015856 Extrasystoles Diseases 0.000 description 1
208000010271 Heart Block Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040738 Sinus arrest Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
206010047281 Ventricular arrhythmia Diseases 0.000 description 1
206010047289 Ventricular extrasystoles Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
230000007815 allergy Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
229940088007 benadryl Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
190000008236 carboplatin Chemical compound 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
208000013219 diaphoresis Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000005801 respiratory difficulty Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000155 toxicity by organ Toxicity 0.000 description 1
230000007675 toxicity by organ Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NL9301086A 1992-08-03 1993-06-22 Methoden voor toediening van taxol. NL9301086A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92362892A	1992-08-03	1992-08-03
US92362892		1992-08-03

Publications (1)

Publication Number	Publication Date
NL9301086A true NL9301086A (nl)	1994-03-01

Family

ID=25448992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL9301086A NL9301086A (nl)	1992-08-03	1993-06-22	Methoden voor toediening van taxol.

Country Status (23)

Country	Link
US (5)	US5641803A (da)
EP (3)	EP0783886A3 (da)
JP (1)	JP2848760B2 (da)
AT (1)	ATE152910T1 (da)
AU (3)	AU641894B3 (da)
BE (1)	BE1006497A5 (da)
CA (1)	CA2086874E (da)
CH (1)	CH686868A5 (da)
DE (2)	DE69310634T2 (da)
DK (2)	DK65293A (da)
ES (2)	ES2105926B1 (da)
FR (1)	FR2694192B1 (da)
GB (1)	GB9311740D0 (da)
GR (2)	GR1001617B (da)
IE (1)	IE80620B1 (da)
IL (1)	IL105879A (da)
IT (1)	IT1276041B1 (da)
MY (1)	MY109862A (da)
NL (1)	NL9301086A (da)
NZ (1)	NZ245795A (da)
PT (1)	PT101289A (da)
SE (1)	SE513082C2 (da)
ZA (1)	ZA93686B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US20070116761A1 (en) *	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5716981A (en) *	1993-07-19	1998-02-10	Angiogenesis Technologies, Inc.	Anti-angiogenic compositions and methods of use
USRE38424E1 (en) *	1994-11-21	2004-02-10	The United States Of America As Represented By The Department Of Health And Human Services	Method for treating taxol side-effects with G-CSF
US5977163A (en)	1996-03-12	1999-11-02	Pg-Txl Company, L. P.	Water soluble paclitaxel prodrugs
US6441025B2 (en) *	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
US20030157187A1 (en) *	1996-12-02	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en)	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
US20030105156A1 (en) *	1997-01-07	2003-06-05	Nagesh Palepu	Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20030087954A1 (en) *	1997-01-07	2003-05-08	Sonus Pharmaceuticals, Inc.	Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) *	1997-01-07	2004-04-27	Sonus Pharmaceuticals, Inc.	Method for treating colorectal carcinoma using a taxane/tocopherol formulation
GB9705903D0 (en)	1997-03-21	1997-05-07	Elliott Gillian D	VP22 Proteins and uses thereof
AU7486898A (en)	1997-05-13	1998-12-08	Stuart D Edwards	Global medical treatment method and apparatus
CN101579335B (zh)	1997-06-27	2016-08-03	阿布拉科斯生物科学有限公司	药剂的制剂及其制备和应用方法
ES2435944T3 (es) *	1997-06-27	2013-12-26	Abraxis Bioscience, Llc	Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
WO1999022759A1 (en) *	1997-10-31	1999-05-14	Walter Reed Army Institute Of Research	Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
MY125921A (en) *	1998-02-05	2006-08-30	Novartis Ag	Compositions containing organic compounds
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US7030155B2 (en) *	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US6121029A (en)	1998-06-18	2000-09-19	Novartis Ag	Genes for the biosynthesis of epothilones
US7314637B1 (en)	1999-06-29	2008-01-01	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US6461637B1 (en) *	2000-09-01	2002-10-08	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US6017948A (en) *	1998-10-30	2000-01-25	Supergen, Inc.	Water-miscible pharmaceutical compositions
US6472420B2 (en) *	1998-11-12	2002-10-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6235776B1 (en) *	1998-11-12	2001-05-22	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
EP1191948A2 (en) *	1999-06-11	2002-04-03	Neorx Corporation	High dose radionuclide complexes for bone marrow suppression
TW422706B (en)	1999-07-01	2001-02-21	Wang Iz Rung	An oil-in-water emulsion type of paclitaxel
US7094885B2 (en) *	1999-07-11	2006-08-22	Neorx Corporation	Skeletal-targeted radiation to treat bone-associated pathologies
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) *	1999-10-12	2003-03-20	Cell Therapeutics, Inc.	Manufacture of polyglutamate-therapeutic agent conjugates
US6828346B2 (en) *	1999-10-25	2004-12-07	Supergen, Inc.	Methods for administration of paclitaxel
US6136846A (en)	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
JP2001247459A (ja)	2000-03-03	2001-09-11	Oakland Uniservices Ltd	癌の組み合わせ療法
US20020077290A1 (en) *	2000-03-17	2002-06-20	Rama Bhatt	Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001253336A1 (en)	2000-04-10	2001-10-23	Teva Pharmaceutical Industries Ltd.	Method 0f administration of paclitaxel-plasma protein formulation
WO2002009700A1 (en)	2000-07-28	2002-02-07	Cancer Research Technology Limited	Cancer treatment by combination therapy
AU2002249935A1 (en) *	2001-01-08	2002-08-19	Neorx Corporation	Radioactively labelled conjugates of phosphonates
AU2002249958B2 (en) *	2001-01-16	2007-11-08	Vascular Therapies, Inc.	Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US7115565B2 (en)	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6548531B2 (en)	2001-02-09	2003-04-15	Hoffmann-La Roche Inc.	Method for cancer therapy
US7666414B2 (en) *	2001-06-01	2010-02-23	Cornell Research Foundation, Inc.	Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) *	2001-06-01	2011-01-26	コーネル・リサーチ・ファンデーション・インコーポレイテッド	前立腺特異的膜抗原に対する修飾抗体およびその使用
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
US20040191218A1 (en) *	2001-09-26	2004-09-30	Emlen James W	Pharmaceutical compositions and methods for treating cancer
EP1478343B1 (en) *	2001-10-15	2017-03-22	Crititech, Inc.	Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
AU2003230691A1 (en) *	2002-03-20	2003-10-08	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
GB2386836B (en)	2002-03-22	2006-07-26	Cancer Res Ventures Ltd	Anti-cancer combinations
WO2003086383A1 (en) *	2002-04-12	2003-10-23	Multimmune Gmbh	Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
PT1507554E (pt) *	2002-05-10	2011-11-21	Agennix Inc	Lactoferrina no tratamento de neoplasmas malignos e outras doenças hiperproliferativas
CZ294371B6 (cs) *	2002-06-10	2004-12-15	Pliva - Lachema, A. S.	Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040047835A1 (en) *	2002-09-06	2004-03-11	Cell Therapeutics, Inc.	Combinatorial drug therapy using polymer drug conjugates
GB2394658A (en)	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
CN1700906A (zh) *	2003-02-03	2005-11-23	新药物公司	稳定的无菌过滤性脂质体包封的紫杉烷和其他抗肿瘤药物
WO2004080445A1 (en) *	2003-03-12	2004-09-23	Molecular Engines Laboratories Sa	Methods and compositions for the treatment of cancer
US7085886B2 (en) *	2003-05-28	2006-08-01	International Buisness Machines Corporation	Autonomic power loss recovery for a multi-cluster storage sub-system
US20050208095A1 (en) *	2003-11-20	2005-09-22	Angiotech International Ag	Polymer compositions and methods for their use
WO2005094882A1 (en) *	2004-03-03	2005-10-13	Millennium Pharmaceuticals, Inc.	Modified antibodies to prostate-specific membrane antigen and uses thereof
US7989490B2 (en) *	2004-06-02	2011-08-02	Cordis Corporation	Injectable formulations of taxanes for cad treatment
US8557861B2 (en) *	2004-09-28	2013-10-15	Mast Therapeutics, Inc.	Low oil emulsion compositions for delivering taxoids and other insoluble drugs
GB0501192D0 (en) *	2005-01-20	2005-03-02	Resolution Chemicals Ltd	Stable prostaglandin-containing compositions
WO2006089290A1 (en) *	2005-02-18	2006-08-24	Abraxis Bioscience Inc..	Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US20070003557A1 (en) *	2005-04-21	2007-01-04	Andres Forero	Method for treating cancer using premedication
US9233094B2 (en)	2005-05-04	2016-01-12	Medigene Ag	Method of administering a cationic liposomal preparation
TWI376239B (en) *	2006-02-01	2012-11-11	Andrew Xian Chen	Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN101442998B (zh) *	2006-03-16	2012-03-14	比奥纽默里克药物公司	抗癌活性加强化合物和制剂及其用法
AU2007228984B2 (en)	2006-03-22	2012-05-03	Syncore Biotechnology Co., Ltd	Treatment of triple receptor negative breast cancer
US7838513B2 (en)	2006-07-07	2010-11-23	Tiltan Pharma Ltd.	Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent
US8242165B2 (en) *	2006-10-26	2012-08-14	Creighton University	Mucoadhesive nanoparticles for cancer treatment
AU2008352597B2 (en)	2008-03-14	2012-03-08	Bionumerik Pharmaceuticals, Inc.	Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja)	2008-03-14	2015-02-12	バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド	癌患者の生存時間を増大させるための組成物及び化合物の使用方法
JP2012520314A (ja)	2009-03-11	2012-09-06	アムビトビオスシエンセスコルポラチオン	癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
NZ602385A (en)	2010-03-29	2014-08-29	Abraxis Bioscience Llc	Methods of treating cancer
WO2011123393A1 (en)	2010-03-29	2011-10-06	Abraxis Bioscience, Llc	Methods of enhancing drug delivery and effectiveness of therapeutic agents
EP4450523A3 (en)	2010-04-02	2025-03-12	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
KR20130088116A (ko)	2010-06-04	2013-08-07	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
TW202214691A (zh)	2014-03-21	2022-04-16	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
BR112018075649A2 (pt)	2016-06-08	2019-04-09	Abbvie Inc.	anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EP3468598A1 (en)	2016-06-08	2019-04-17	AbbVie Inc.	Anti-cd98 antibodies and antibody drug conjugates
CA3027044A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214458A2 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
TWI762487B (zh)	2016-06-08	2022-05-01	美商艾伯維有限公司	抗-b7-h3抗體及抗體藥物結合物
US11154511B2 (en)	2016-09-29	2021-10-26	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	Albumin pharmaceutical composition and preparation method therefor
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629818B1 (fr) *	1988-04-06	1990-11-16	Centre Nat Rech Scient	Procede de preparation du taxol
WO1992019765A1 (en) *	1991-05-08	1992-11-12	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

1993
- 1993-01-07 CA CA002086874A patent/CA2086874E/en not_active Expired - Fee Related
- 1993-01-29 AU AU32102/93A patent/AU641894B3/en not_active Ceased
- 1993-01-29 NZ NZ245795A patent/NZ245795A/xx not_active IP Right Cessation
- 1993-01-29 AU AU32168/93A patent/AU3216893A/en not_active Abandoned
- 1993-02-01 ZA ZA93686A patent/ZA93686B/xx unknown
- 1993-02-02 MY MYPI93000157A patent/MY109862A/en unknown
- 1993-06-02 IL IL10587993A patent/IL105879A/en not_active IP Right Cessation
- 1993-06-04 DK DK065293A patent/DK65293A/da not_active Application Discontinuation
- 1993-06-07 GB GB939311740A patent/GB9311740D0/en active Pending
- 1993-06-08 SE SE9301951A patent/SE513082C2/sv not_active IP Right Cessation
- 1993-06-08 IE IE930433A patent/IE80620B1/en not_active IP Right Cessation
- 1993-06-10 GR GR930100239A patent/GR1001617B/el not_active IP Right Cessation
- 1993-06-15 PT PT101289A patent/PT101289A/pt not_active Application Discontinuation
- 1993-06-22 NL NL9301086A patent/NL9301086A/nl not_active Application Discontinuation
- 1993-07-15 JP JP5174994A patent/JP2848760B2/ja not_active Expired - Lifetime
- 1993-07-19 ES ES09301618A patent/ES2105926B1/es not_active Expired - Fee Related
- 1993-07-29 DE DE69310634T patent/DE69310634T2/de not_active Revoked
- 1993-07-29 EP EP97104512A patent/EP0783886A3/en not_active Withdrawn
- 1993-07-29 FR FR9309372A patent/FR2694192B1/fr not_active Expired - Fee Related
- 1993-07-29 EP EP93401978A patent/EP0584001B1/en not_active Revoked
- 1993-07-29 AT AT93401978T patent/ATE152910T1/de not_active IP Right Cessation
- 1993-07-29 DK DK93401978.7T patent/DK0584001T3/da active
- 1993-07-29 IT IT93MI001714A patent/IT1276041B1/it active IP Right Grant
- 1993-07-29 EP EP97104511A patent/EP0783885A3/en not_active Withdrawn
- 1993-07-29 ES ES93401978T patent/ES2101261T3/es not_active Expired - Lifetime
- 1993-07-30 BE BE9300800A patent/BE1006497A5/fr active
- 1993-08-02 DE DE4325927A patent/DE4325927B4/de not_active Revoked
- 1993-08-03 CH CH02325/93A patent/CH686868A5/de not_active IP Right Cessation
1995
- 1995-10-18 US US08/544,594 patent/US5641803A/en not_active Expired - Lifetime
- 1995-11-20 US US08/559,890 patent/US5621001A/en not_active Expired - Lifetime
1996
- 1996-01-19 AU AU42070/96A patent/AU704393C/en not_active Ceased
- 1996-09-19 US US08/715,914 patent/US5670537A/en not_active Expired - Lifetime
- 1996-11-22 US US08/755,740 patent/US5665761A/en not_active Expired - Lifetime
1997
- 1997-08-13 GR GR970402058T patent/GR3024415T3/el unknown
2000
- 2000-02-07 US US09/499,373 patent/US6414014B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FR2694192B1 (fr)	1995-01-27
NZ245795A (en)	1999-05-28
FR2694192A1 (fr)	1994-02-04
US5670537A (en)	1997-09-23
ZA93686B (en)	1993-09-06
JPH07233064A (ja)	1995-09-05
US6414014B1 (en)	2002-07-02
GB9311740D0 (en)	1993-07-21
CA2086874C (en)	1998-09-01
EP0584001A1 (en)	1994-02-23
AU4207096A (en)	1996-04-26
DE69310634T2 (de)	1998-01-02
ES2105926B1 (es)	1998-07-01
ES2101261T3 (es)	1997-07-01
DE4325927A1 (de)	1994-03-10
EP0584001B1 (en)	1997-05-14
IL105879A0 (en)	1993-10-20
JP2848760B2 (ja)	1999-01-20
SE9301951D0 (sv)	1993-06-08
ES2105926A1 (es)	1997-10-16
ITMI931714A0 (it)	1993-07-29
SE513082C2 (sv)	2000-07-03
US5641803A (en)	1997-06-24
CH686868A5 (de)	1996-07-31
CA2086874E (en)	2000-01-04
DK65293D0 (da)	1993-06-04
BE1006497A5 (fr)	1994-09-13
DK65293A (da)	1994-02-04
MY109862A (en)	1997-09-30
US5621001A (en)	1997-04-15
ATE152910T1 (de)	1997-05-15
IL105879A (en)	1998-08-16
GR3024415T3 (en)	1997-11-28
AU704393C (en)	2002-07-25
DK0584001T3 (da)	1997-08-25
DE69310634D1 (de)	1997-06-19
AU704393B2 (en)	1999-04-22
SE9301951L (sv)	1994-02-07
AU641894B3 (en)	1993-09-30
GR1001617B (el)	1994-07-29
AU3216893A (en)	1994-02-10
EP0783886A3 (en)	1997-07-23
US5665761A (en)	1997-09-09
PT101289A (pt)	1994-04-29
IE930433A1 (en)	1994-02-09
ITMI931714A1 (it)	1995-01-29
EP0783886A2 (en)	1997-07-16
IT1276041B1 (it)	1997-10-24
DE4325927B4 (de)	2004-04-15
EP0783885A2 (en)	1997-07-16
IE80620B1 (en)	1998-10-21
CA2086874A1 (en)	1994-02-04
EP0783885A3 (en)	1997-08-06

Legal Events

Date	Code	Title	Description
1996-03-01	BC	A request for examination has been filed
1997-08-01	BI	The patent application has been withdrawn

Publication	Publication Date	Title
AU704393B2 (en)	1999-04-22	Methods for administration of taxol
CA2122519C (en)	2001-02-20	Cancer treatment and metastasis prevention
CA2926771C (en)	2022-07-05	Cancer treatment with combination of plinabulin and taxane
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
Tamura et al.	1995	Phase I study of paclitaxel by three‐hour infusion: hypotension just after infusion is one of the major dose‐limiting toxicities
Abidi et al.	2013	A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function
Murphy et al.	2010	Octreotide
Khan et al.	2023	Advancements in sickle cell disease (SCD) treatment: a review of novel pharmacotherapies and their impact on patient outcomes
Link Jr et al.	1995	Cutaneous manifestations of taxol® therapy
GB2269319A (en)	1994-02-09	Compositions containing taxol
JP3811500B2 (ja)	2006-08-23	動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物
HK1001199A (en)	1998-06-05	Use of taxol for the manufacture of a medicament for the treatment of cancer
HK1001200A (en)	1998-06-05	Use of taxol for the manufacture of a medicament for the treatment of cancer
Zahr et al.	2024	Oral liposomal iron versus injectable iron sucrose for anemia treatment in non-dialysis chronic kidney disease patients: a non-inferiority study
AU7179200A (en)	2001-02-08	Method of treatment of breast cancer
EP3965734A1 (en)	2022-03-16	Method for increasing cancer patient's haemoglobin level
Billings et al.	2018	Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
JPS60174726A (ja)	1985-09-09	注射用医薬組成物
Boehnke	1995	The Evolving Role of Paclitaxel in Breast Cancer and the Ambulatory Care Setting
Ma et al.	2018	Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion vs. Subcutaneous Injection in Adults with Type 2 Diabetes and High Insulin Requirements
Dittrich et al.	2000	Therapy of the small cell lung cancer—Comparison two established chemotherapy regime (ACO vs. CEV)
Strowig	0	Three-drug plan for glycemic control
HK1114769A1 (en)	2008-11-14	Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
HK1114769B (en)	2011-08-05	Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative